SBRT for Central and Ultra‐Central Early‐Stage Inoperable Non‐Small Cell Lung Cancer

Accuray April 23rd, 2024

April 23rd, 2024, 8.30am EST | 2.30pm CEST | 8.30pm HKT 

Presenter: Yuan Zhi Yong, M.D., Professor, Chair of Radiation Oncology Department, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

Moderator: Joost J. Nuyttens, M.D., Ph.D., Radiation Oncologist, Erasmus MC Cancer Institute, Rotterdam, The Netherlands


For patients who are medically inoperable and have central or ultra-central lung cancer (CLC/UCLC), treatment options can be limited. However, in recent years, stereotactic ablative radiotherapy (SABR) or stereotactic body radiotherapy (SBRT) has improved the clinical efficacy and survival rate of CLC/UCLC patients. Despite this progress, the appropriate radiation therapy dosage remains a topic of debate.

Over the past decade, the Tianjin Medical University Cancer Institute & Hospital has conducted extensive research into the clinical application of SBRT for CLC/UCLC patients. Their findings may provide valuable insight into managing these patients. In this upcoming webinar, Dr. Yuan will share their experience and results of SBRT for CLC/UCLC in Non-Small Cell Lung Cancer

This webinar is pending approval from CAMPEP for 1 MPCEC hour and approved by ASRT for 1 category A credit.

DISCLAIMER: The statements and articles in the corporate news forum do not necessarily reflect the views of, and are not endorsed by ISRS. Please consult the specific corporate entity for relevant disclosures and restrictions related to these news features.